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The liver is a vital organ that carries out over 500 essential tasks, including fat metabolism, 
blood filtering, bile production, and some protein production.  Although the structure of the liver 
and the role of each type of cells in the liver are well known, the biomedical and mechanical 
interplays within liver tissues remain unclear. Chronic liver diseases are a significant public health 
challenge. All chronic liver diseases lead to liver fibrosis due to excessive fiber accumulation, 
resulting in cirrhosis and loss of liver function.  Only early stage liver fibrosis is reversible. 
However, early-stage liver fibrosis is difficult to diagnose. How the progression of fibrosis changes 
the mechanical properties of the liver tissue and altering the dynamics of blood flow is still not 
well understood. The objective of this dissertation is to integrate the understanding of liver diseases 
and mechanical modeling to develop several models relating liver fibrosis to blood flow. In 
collaboration with clinicians specialized in hepatic fibrosis, we integrated computational modeling 
and clinicopathologic image analysis and proposed a new technology for early stage fibrosis 
detection.  The key results of this research include: (1) A mathematical model of liver fibrosis 
progression connecting the cellular and molecular mechanisms of fibrosis to tissue rigidity; (2) A 
novel machine learning-based algorithm to automatically stage liver fibrosis based on pathology 
images; (3) A physics model to illustrate how the liver stiffness affects the blood flow pattern, 
predicting a direct relationship between fibrosis stage and ultrasound Doppler measurement of 
liver blood flow; (4) Statistical analysis of clinical ultrasound Doppler data from fibrosis patients 
confirming our model prediction.  These results lead to a novel noninvasive technology for 
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1 INTRODUCTION  
Liver fibrosis arises from chronic liver damage[1]. Late-stage fibrosis, or cirrhosis, affects 
liver functions and is a significant public health problem[2]. The liver fibrosis is mainly induced 
by many reasons, including alcohol abuse, chronic hepatitis C virus (HCV) infection, toxin, and 
nonalcoholic steatohepatitis (NASH)[3, 4]. The fiber deposition distorts the hepatic architecture, 
and the subsequent development of hepatic fibrosis defines cirrhosis[5-7]. Cirrhosis is a condition 
in which the liver loses function due to long-term damage and causes the hepatic insufficiency and 
portal hypertension, respectively[8-12]. 
Hepatic fibrosis was historically known to be a passive and irreversible disease due to the 
collapse of hepatic parenchyma and the abundant fibrous tissue[13-17]. Fibrosis describes a 
progression in which the injured tissue was replaced or encapsulated by collagen. These responses 
result in the continuation of fibrogenesis. Presently there is no effective treatment for liver 
fibrosis[16, 18]. In the 1970s, the clinical reports first presented that the liver has the potentially 
reversible ability in advanced liver fibrosis[19]. With the increasing understanding of the liver 
structure, the function cells, including Kupffer cell and hepatic stellate cells (HSCs), were defined 
as the primary activity cells for producing collagen in the liver[20, 21]. Liver fibrosis is a complex 
process involving multiple time scales, biomechanical mechanisms, physical interaction, including 
cell-cell and cell-matrix, and intracellular signal transduction[22-24]. A thorough review of the 
process is given in Chapter II. However, how fibrosis progression affects the medical properties 
of the liver is not thoroughly understood and the mechanism of altering the dynamics of blood 
flow is still unclear. In this work, we analyze clinical data to understand the progression of liver 
fibrosis and develop a novel method for noninvasive diagnosis. 
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We simulate the fibrosis progression in silico and develop explanatory models at tissue and 
organ levels. The experimental data include biopsy and ultrasound images from our collaborators. 
We get the spatial information from biopsy:  the fiber locations in a liver, the position of fiber 
relative to the vein at various fibrosis stages. The corresponding time-dependent information such 
as blood flow velocity and frequency in hepatic veins is extracted from the ultrasound image of 
the same patient. Integrating the spatial-time information improves the understanding of the 
dynamics of blood flow in liver and related fibrosis process. 
Currently, the exact number of liver fibrosis patients worldwide is unknown but expected 
to be enormous. The cirrhosis patients were estimated at 400,000 in the USA[25]. This number 
exclude the high prevalence of undiagnosed cirrhosis in both NASH and viral hepatitis. In some 
Asian countries, alcohol liver fibrosis and viral hepatitis B occur at an even higher rate than in 
Europe. In 2015, up to 75% of cirrhosis patients had liver cancer. Due to the challenge of early-
stage fibrosis detection, the actual number should be much higher than what we have [26]。 
In clinical cases, liver fibrosis, especially at its early stages, is highly asymptomatic and 
unalarming till obvious symptoms of liver diseases develop [27]. Patients hardly pay close 
attention without any pathological feature. Liver fibrosis is usually detected from elastography, 
liver disease suggestion, and biopsy [28-30]. The accuracy of early-stage detection using 
elastography is at question. The diagnosis of fibrosis from suggesting liver diseases depends on 
the doctor’s experience. About one fifth of patients with HCV take high risk to make biopsy. Thus, 
a liver fibrosis diagnosis method that is convenient, highly accurate, offering low cost and low risk 
has long been sought after. 
This dissertation tries to understand the principle mechanism of liver fibrosis and build 
models to solve the problems in clinical liver fibrosis diagnosis. Our work develops a model to 
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describe the progression of liver fibrosis, including the behavior of dead cells and the distribution 
of fiber. The model demonstrated the details of fiber growth and produced a key to explain the 
blood flow in liver fibrosis stages. The blood flow model analyzes the dynamics of blood and liver 
fiber interaction. Using the model, we investigate the mechanisms responsible for promoting liver 
fibrosis. In the investigation, the liver biopsy is the standard reference. To increase the accuracy 
of the grading of the liver biopsy, we introduce machine learning to train the tissue slices. 
The dissertation is organized by the following story. Chapter II describes a background of 
the biological processes and blood flow relevant to liver fibrosis topic. The chapter highlights the 
dead cell as a key to enable the fibroblast and hepatic stellate cell (HSC) to progress liver fibrosis. 
Then the structure of the fiber and hepatic vein was discussed in a different stage of liver fibrosis.  
Chapter III presents an overview of mathematical modeling techniques. The models try to 
describe the progression of liver fibrosis within whole biological systems, and to study the 
dynamics of liver tissue at varying time scales. This chapter also reviews previous mathematical 
models of liver fibrosis and identifies their strengths and limitations. The advantage of the pixels 
model and the bead-spring model we used can display hepatic fiber activity more clearly. The 
blood flow model is based on the premise of fiber-cell interactions during liver fibrosis. These 
interactions are regulated at the sigla cell level. 
Chapter IV presents a new machine learning method for auto-grading liver fibrosis via 
biopsy. The clinical and mathematical research in liver fibrosis based on biopsy introduces the 
need of accurate biopsy liver fibrosis grading. Currently, the classification of liver fibrosis stage 
was scored by the Ishak system and METAVIR system. However, the accuracy of grading depends 
on the experience of doctors, so the new grading method using machine learning, building on the 
logical reasoning of fiber growth, is designed to promote the diagnostic accuracy and reduce test 
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time. Our machine learning model converts the qualitative criteria into quantitative scores in the 
liver biopsy characterization. 
Then in Chapter V, the first prospective study applies a blood flow model for staging liver 
fibrosis in patients. The extended model was produced and validated against diagnosis from liver 
biopsy. Thus, the model study how the fiber influences the dynamics of blood and thus the grading 
of liver fibrosis. In this chapter, the existing methods of liver fibrosis are also introduced. The 
newly proposed algorithms in this work analyze the ultrasound Doppler images from hepatic 
fibrosis patients. Liver biopsy is usually used as the gold standard reference for pathology liver 
fibrosis grading, as well as other references such as elastography and biomarkers, were employed 
to test the accuracy our diagnostic method. The results support the hypothesis of our models. We 
then briefly discuss the dynamics of blood flow, and propose a new noninvasive diagnostic tool 
for liver fibrosis. 
The summary chapter VII discusses the impact and outlook of this research.  
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2 BIOLOGICAL BACKGROUND OF LIVER 
2.1 Liver fibrosis 
Liver fibrosis, the accumulation of excess extracellular matrix (ECM) in the liver, is 
characteristic of most chronic liver diseases, including chronic hepatitis B or C viral infection, 
alcoholic abuse, and nonalcoholic fatty liver disease (NAFLD), or nonalcoholic steatohepatitis[3, 
31-34]. Liver fibrosis is the consequence of injury to the healthy liver. Chronic injury leads to 
progression of fibrosis, which eventually results in the loss of liver function. Currently, the 
diagnostic of liver fibrosis is based on medical imaging and liver biopsy[37]; however, there is no 
effective detection to quantitatively measure the stage of liver fibrosis, especially at early stage. 
The gold standard for diagnosis of liver fibrosis is a liver biopsy. The Ishak scoring system 
and METAVIR scoring system are used to grade the stage of liver fibrosis [Table 2.1-1]. Liver 
fibrosis is classified into four stages by the Ishak system or METAVIR system, F1, F2, F3, and 
F4, respectively[4, 35, 36]. F0 is no fibrosis. The early stage of liver fibrosis is F1-F2. The 
advanced liver fibrosis is F3-F4. When fibrosis progresses to architecture with the formation of 

















No fibrosis (normal) 0 F0 
Fibrous expansion of some 
portal areas ±short fibrous 
septa 
1 F1 
Fibrous expansion of most 
portal areas ±short fibrosis 
septa 
2 F2 
Fibrous expansion of most 
portal areas with occasional 
portal to portal (P-P) bridging  
3 
Fibrous expansion of portal 
areas with marked bridging 
(portal to portal (P-P) as well 
as portal to central (P-C) 
4 F3 
Marked bridging (P-P and/or 
P-C), with occasional nodules 
(incomplete cirrhosis) 
5 
Cirrhosis, probable of definite 6 F4 
 
2.1.1 Liver biopsy 
The biopsy is treated with the gold standard of liver fibrosis reference and assessed the 
grading of inflammation and staging of fibrosis. However, the biopsy is limited to diagnosis 
sampling variability in all liver diseases [4, 39-41]. Thus, the accuracy of biopsy diagnosis only 
achieved 65% and 75% when the sampling size is 15mm and 25mm in length, respectively[4]. 
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Despite this shortcoming, the biopsy is still required to grade liver fibrosis and to provide its 
cause. Only the clear signs of cirrhosis do not need the biopsy confirmation of fibrosis, such as 
ascites and coagulopathy[42]. 
A liver biopsy is obtained by the larger-diameter needle under the ultrasound guidance[43, 
44]. Each patient usually is cut at least two times, to get more sampling variability. The suction 
needle is used to prevent tissue fragmentation[45].  
2.2 The mechanism of Liver Fibrosis 
The formation mechanism of cirrhosis is progressive fibrosis. The collagen of healthy 
hepatic tissue mainly distributes around the portal area and central vein[46, 47]. During the 
fibrosis, collagen observably increases and deposit in the lobules. At cirrhosis, the liver loses 
function due to the forbidden of exchange between vessel and liver cells[28]. 
2.2.1 Hepatic tissue 
At the hepatic fibrosis condition, although the fibrosis tissue forms many little bands, they 
still aren’t fully connected. When fibrosis continues to progress, the fiber bands will bridge to each 
other to rebuild the lobule of structure. 
At the healthy condition, the liver is divided at the histological scale as lobule by vein, and 
the pattern of the lobule is hexagon in two-dimensional (Figure 2-1). In the lobule, there are 
vessels, hepatocyte, Kupffer cell, fibroblast, hepatic stellate cell, and collagen. The function of the 
vessel is transporting nutriment and cells[48]. Typically, Kupffer cells transport in liver tissue 
through the vessel. Kupffer cells are characteristic macrophages located in the wall of the sinusoid, 
which is a small blood vessel in the liver, and the activation is responsible for the liver injury[49-
51]. Fibroblast is a type of cell which synthesizes ECM and collagen[52]. Hepatic stellate cells are 
found in a small area between the sinusoids and hepatocytes and also is activated by cytokines 
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(Figure 2-2). Collagen is the main structural protein in ECM and displays a triple helix chain[53]. 
In the liver, myofibroblasts are function cell which produces excessive amounts of collagen in 
wound tissue[54], and then the wound concomitant alignment of the collagen fibers by integrin-
mediated pulling on the collagen bundles[55].  
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Figure 2-1 Microscopic anatomy of the liver. The hepatic lobule is building the liver tissue, 
consisting of central vein, sinusoids, portal field and plates of hepatocytes[56]. This image are 




Figure 2-2 The mammalian liver. Portal field includes portal venule, hepatic arteriole 
and bile ductule. The Kupffer cell is lining in the sinusoid and release cytokines. The disse is a 
space between the sinusoid and the hepatocytes. [57]. 
 
2.2.2 Kupffer cell 
In the liver, injury and toxicity transforms hepatic cells to the dead agent. The function of 
Kupffer cell is surveying the area and phagocytizing dead cells and producing the cytokines in the 
process[49, 58]. The cytokines are TNF-α and TGF-β1[59]. Biologically, inadequate clearance of 
dead cells can lead to liberating some damage-associated molecular pattern molecules such as high 
mobility group box protein 1 (HMGB1)[60]. 
In the liver, the cellular damage due to liver injured leads to the upregulation and release 
of damage-associated molecules such as HMGB1[61]. HMGB1 attracts the Kupffer cells to 
phagocytose dead cells and produce cytokines, including TNF-α and TGF-β1 in the process[62]. 
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HMGB1 and TNF-α can effectively activate fibroblast and HSC to induce their transformation to 
myofibroblast. TGF-β1 makes myofibroblast proliferation and deposition of ECM. Figure 2-3 
summarizes the cellular mechanisms of the fibrosis process[63].  
 




Collagen is the main structural protein in ECM and displays a triple helix chain. Most of 
the collagen molecules are assembled in the form of long thin fibrils of similar structure. In 
contrast, collagen type-IV forms a two-dimensional reticulum. The basic structural unit of collagen 
is a triple helix, which is a long (300nm), thin (1.5 nm diameter) protein[64]. All collagen is due 
mainly to segments to connect each other by chemical activity and then fold into different kinds 
of three-dimensional structures[65]. 
2.2.4 Collagen interactions and fibrils 
Many three-stranded collagen molecules bundle together to form fibrils side by side with 
50-200 nm[66]. In fibrils, about one-quarter of the length of collagen molecules is connected. So 
the characteristic pattern of the collagen bundle is repeated such staggering array. 
Short segments on the collagen chains play a critical role in the formation of collagen fiber. 
These short segments are just short chains and contain special amino acid hydroxylysine. Covalent 
aldol cross-links are formed by lysyl oxidase and oxygen[67] (Figure 2-4). And these covalent 
cross-links keep this side-by-side collagen chain stability and generate a strong fibril (Figure 2-5). 
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Figure 2-5 Collagen chains. A. collagen fibers, B. Collagen fibril, C. the tropocollagen 
molecule[68]. Histology @Yale 
 
Collagen fibrils which have tremendous tensile strength are packed side by side in parallel 
bundles to form collagen fibers. So, in collagen structure, there is no crosslinker, all collagen fibrils 
are connected by covalent cross-links. 
2.2.5 The macro-pattern of collagen 
The pattern of the lobule is the hexagon, which is divided by veins in the liver[69]. In 
cirrhosis, lots of collagen fibrils segments replace the dead cells, which are around the vein to form 
collagen bundles by covalent cross-links. The distribution of collagen fiber follows the vessel 
structure. In two dimensional, the pattern of collagen bundle is  hexagonal. In three-dimensional, 
the structure of the collagen bundle looks disordered. However, all the collagen bundles spread 
from the boundary of the lobule to the central vein. 
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3 MODELING LIVER FIBROSIS 
Liver fibrosis has been a significant challenge in public health. However, the change of 
mechanical properties of liver tissue is still a myth. Integrating the understanding of liver fibrosis, 
we built a mechanical model for the liver. The model simulates the toxin diffusion in the liver that 
leads to hepatic tissue damage and collagen deposition. Also, we used the bead-spring model to 
test the mechanical properties of the liver during fibrosis. The mathematical models and simulation 
results can be used as a research tool to synthesize in-depth research for the liver. 
Liver fibrosis is a wound healing response in which damaged liver regions are encapsulated 
by an extracellular matrix or scar. Chronic liver injuries can be caused by a viral infection, toxin 
exposure, NASH, an autoimmune disorder, and metabolic disorders[70] and physical injury.  
Viral hepatitis commonly refers to the hepatitis A virus (HAV), hepatitis B virus (HBV) 
and hepatitis C virus (HCV)[71-73]. HAV is caused by contaminated food or water. HBV and 
HCV are infected by body fluids.  HAV and HCV are RNA viruses. HBV is a DNA virus. They 
activate CD4+T cells to transfer to serval kinds of subtype T cells, which have a different 
function[74]. The activated T cell can produce inflammatory cytokines[75]. The inflammatory 
cytokines such as IL-17 and IL-22 promote liver fibrosis by activating hepatic stem cells (HSCs), 
which regulate chemokines and fibrogenic genes or result in hepatocellular damage[76-79]. 
Hepatitis virus enters the liver through blood, then influence the liver health[80]. The earliest 




Figure 3-1 Liver biopsy shows inflammation and interface hepatitis. The arrow points to 
eosinophil clusters. Image courtesy of Dr. Ye Lihong from Shijiazhuang fifth hospital. 
 
In the United States and Japan, alcohol is the primary cause of liver fibrosis.  Almost 10% 
- 35% of heavy drinkers have alcoholic hepatitis (ALH)[28].  While an alcoholic cannot directly 
relate to the development of hepatic fibrosis, this action seems more popular than others in liver 
disease. With chronic ethanol intake, gut-derived endotoxin was absorbed into the portal 
circulation.  In the early stage of ALH, the activated Kupffer cells produce pro-inflammatory 
cytokines and chemokines, which result in liver injury. Then macrophage and neutrophils are 
increased by those chemokines and cytokines in fatty liver and steatosis (figure3-2).  The amplified 
systemic inflammation and immunodeficiency from alcoholic hepatitis patients were observed.  
17 
 
Figure 3-2 Illustration of alcoholic liver disease progression [81]. 
 
Endotoxin was produced because of impaired cytotoxic function [82]. The endotoxin leads 
to a high injection rate in alcoholic hepatitis patients. It enters the liver through bile. Based on the 
direction of bile flow, the concentration of endotoxin in bile is highest in the central of the lobule. 
Nonalcoholic steatohepatitis (NASH) is another reason to result in liver cirrhosis. It leads 
to a fatty liver that is not caused by alcohol. It is caused by a metabolic disorder, malnutrition, and 
industrial poisoning [83]. 
In summary, the deposition of collagen fibers starts from the portal area in most hepatitis 
diseases. In this project, we model the progression of liver fibrosis as a result of toxic substance. 
3.1 Existing models 
Currently, there is no comprehensive mathematical model for liver fibrosis. One model by 
Ying et al [84] only focus on one stage of cirrhosis by the simple structure. They developed a 
model and predict the elastic behavior and its modulus evolution of cirrhotic human liver 
comparing with experiment data. They derived modulus evolution for the strain energy function 
through mathematics by using cubic structure[84]  (Figure 3-3). 
18 
 
Figure 3-3 Eight-particle interaction model of composites for deformation. They assume 
the matrix and particle have the isotropic elasticity tensors.[84]. 
 
Another published model also describes the liver fibrosis process. Vodovotz’s research use 
to translational systems biology to generate and simulate the liver fibrosis processes[85]. Park et 
al. tried to study the changes in drug disposition properties due to liver disease using a normal and 
diseased version of abstract, agent-oriented In Silico Livers (ISL), and validated the models’ 
mechanisms against disposition data from rat livers, normal and diseased. They dynamically traced 
the disposition differences for diltiazem and sucrose across five levels, mapping to measure of 
histopathology, and thus measured disease-causing differences in local ISL effects. The model can 
explore how hepatic drug disposition differs in less or more advanced stages of liver diseases, 
contributing to unraveling the complex correlation between liver disease and drug disposition.[89]. 
Bhattacharya et al. studied chemical- and drug-induced toxicity via “toxicity pathways” using 
computational systems biology approaches. They described three case studies in computational 
modeling approaches to understand perturbation of intracellular toxicity pathways on toxicity of 
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the liver (hepatotoxicity), including Computational systems biology pathway (CSBP) models, 
ordinary differential equations (ODEs), and Agent-based modeling (ABM). These computational 
models can determine toxicity pathways and improve dose-response estimation.[90]. Wambaugh 
and Shah proposed a graphical model of the sinusoidal network to simulate a spatially extended 
hepatic lobule, integrating in vitro liver experiments with agent-based cellular models. They aim 
to develop a framework to quantitatively and efficiently simulate the microanatomic distribution 
of various chemicals in a canonical lobule for time period ranging from hours up to months. They 
assumed a discrete topological architecture of the hepatic via a graphical model, to explicitly 
explore the concentration distribution of environmental chemicals. Then materials flow one-
dimensionally through sinusoidal elements of transformed network. Thus the relationship between 
individual exposure and microdosimetry is estimated by connecting the virtual lobule to a 
physiologically-based pharmacokinetic (PBPK) model. The method provides a possibility to 
cheaply access variable inter- and intracellular chemical dynamics with potential to alter lobule 
geometry. The limitations are biologically additional data such as information on the statistical 
distribution of lobule morphology and the cell response to local chemical levels is needed. Besides, 
whether three-dimensional lobule paradigm in simulation is needed remains unknown.[91]. 
Friedman et al. focused on the biochemical regulations of fibrosis[92], using a system of partial 
differential equations to explore the efficacy of potential drugs in the progression of liver fibrosis. 
To simulate the progression of fibrosis, one would need to describe the details at the sub-
lobular scale. The agent-based models (ABMs) is a very popular model aiming to test the 
hypotheses regarding dynamic changes in several arears of clinical interests[86-88]. Joyeeta et al. 
built a multiscale agent-based model to compute liver inflammation on a structural skeleton of 
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physical forces[93]. The model used agents representing hepatocytes and collagen to test any 
changes in size or elasticity in liver fibrosis.  
The previous models mainly focus on elastic behavior and the concentration of drug in 
liver fibrosis. Our model is built for viral inflammation leading to liver fibrosis, which starts to 
affect how the inflammatory substance diffuse in the liver and how the fiber grows following the 
distribution of dead hepatic cells. The model will perform the whole progression of fiber growth 
which is from inflammatory substance diffusion. The simulation images will be used to compare 
the real liver tissue and join the training group for machine learning. 
 
3.2 Pixel – diffusion model 
Our biophysical model of liver tissue is approximated to cell death because of toxin 
diffusion. The simulation of liver fibrosis has two models using pixel-diffusion model and bead-
spring model. Pixel-diffusion model is used to describe the dynamics of toxin spreading from a 
hepatic vein using biological rules that dictate their behaviors. Toxin diffusion evolves at a 
constant rate and responds to the distance to the hepatic vein. The concentration of the toxin 
changing environment leads to the death of hepatic cells. From a simple set of rules, Pixel-diffusion 
model can exhibit highly complex phenomena. With the increasing understanding of the biological 
system, the realistic and relevant model becomes more command to increase the level of 
description. In supporting the computational ability of computers, Pixel-diffusion model preforms 
the whole process of toxin spread with solving Pixel-diffusion models. Bead-spring model 
describes the physical properties of liver tissue with the finite element method (FEM). FEM is the 
most comprehensive method for solving the traditional fields of structural analysis. Bead-spring 
model simulates the deformation of liver structure in a different stage of liver fibrosis.  
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3.2.1 Toxin diffusion 
Our simplified biophysical model of liver tissue is approximated as a hexagonal lattice of 
lobules, the vertices of the hexagons correspond to portal veins, and the centroid of the hexagons 
are the locations of the central veins (Figure 3-4). The various research shows toxin results in 
hepatocyte damage and fibrosis[94-96]. In the pixel-diffusion model, the toxin as the pixel agent 
enters the lobule from the portal vein and flows out through the central vein. In the simulation, 
assuming toxic substances are small molecules that diffuse freely in the tissue, with the sources at 









) − 𝛾𝐶 ,                 (1) 
where C is the toxin concentration, D is the diffusion coefficient, γ is the decay rate.  We used 
MATLAB to solve this PDE, After running 1000 simulation steps, the result which approach the 
steady state, shows that the concentration of the substance which moving in and out of capillary 
walls as the blood exchanges materials with hepatic cells depends on the distance to the portal vein 
(Figure 3-5). In the simulation, we varied the initial concentration of toxin at portal vein, also set 
D and γ in the model. The initial concentration of toxin relate to how much toxin in the portal vein. 
The diffusion coefficient D is a constant which doesn’t depend on the density and describe the 





Figure 3-4 The hexagon of liver lobules. The central vein (*) is in the center of the 
hexagonal lobule. The arrow refers to the boundary of the lobule. The vertices of the hexagon are 









Figure 3-5 The concentration of toxin as thesolution of Equation with 1000 simulation 
steps(1). Concentration of toxin is c in equation (1). The concentration of toxins represented in 
height. 
 
We further assume that cell damage is linearly proportional to the concentration. The 
pattern of activation of myofibroblasts is the same as the concentration field. Hence the production 
and deposition of the collagen also follow this concentration pattern. The collagen forms fiber by 
fiber, stochastically. 
 
3.2.2 The death of the hepatic cell 
The process of hepatic fibrosis evolves at the interaction of toxin and the death of the liver 
cell. Cell death results in fiber deposited by myofibroblast; meanwhile, it also describes why the 
fibers encapsulate the lobule at first. In our model, the hepatic cell was introduced to the 
regeneration function, and the dead cell has a high probability to appear in portal area. The model 
assumes that some hepatic cells die due to the toxin damage at each unit time. The nearest dead 
cell from the vein is kept, and the others are regenerated to be hepatic health cells. In the code of 
simulation, we assume that hepatic cells die when the concentration of toxin exceeds a threshold 
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value. The threshold value depends on the toxin type and affects the elastic of liver tissue. Previous 
experimental studies used a toxin to induced liver injured and indicated the progression of liver 
fibrosis in response to hepatic injury[92] (Figure 3-6). In the figure, the infected cells were 
distributed around portal vein and form a connect channel between two portal veins, which like 
our simulation result. 
 
Figure 3-6 H&E staining of liver tissue.  Necrotic areas are marked by dotted lines. Black 
bars represent 0.5 mm[92]. 
 
3.3 Bead–spring model 
The structure of bead-spring model was derived from pixel-diffusion model results. After 
each simulation step, the pixel of the dead cell will transfer to fiber pixel because of the interaction 
of myofibroblast. The number of fiber pixels that were calculated in the small area defines the 
stiffness of unit length. The calculating area was defined by the threshold of concentration of toxin 
in pixel-diffusion model. The area was divided into segments by the portal vein. In bead-spring 
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model, a complex spring was used to simulate the stiffness of liver tissue. We assume the number 
of total pixels in a limit area is 𝑛𝑝, the number of fiber pixels is 𝑛𝑓, the original stiffness coefficient 
of spring is 𝑓, the stiffness coefficient of fiber spring is 𝑓𝑓𝑖𝑏𝑒𝑟 , so the stiffness coefficient of 









The crosslinker proteins, e. g. lysyl oxidase (LOX) is assumed to be uniformly distributed, 
which forms covalent bonds between fibers. In the mechanical model, we assume each joint 
between fibers/springs is cross-linked. 
We use complex spring to represent the mechanical of the fiber bundle network as fibrosis 
progresses. (Figure 3-7) In the liver fibrosis, the black spring was combined with tissue spring and 
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where 𝑘𝑠𝑝𝑟𝑖𝑛𝑔 is the elastic coefficient for spring, 𝑘𝑡𝑖𝑠𝑠𝑢𝑒 is the elastic coefficient for tissue and 
𝑘𝑓𝑖𝑏𝑒𝑟 𝑖𝑠 𝑡ℎ𝑒 𝑒𝑙𝑎𝑠𝑡𝑖𝑐 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑓𝑜𝑟 𝑓𝑖𝑏𝑒𝑟. 
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Figure 3-7 A: An illustration of a 2D mechanical pattern described as a bead-spring 
model. The red beads are each joint to show typical chain behavior. Black springs correspond to 
collagen fibers distributed around the boundary of the lobules. Red springs present elastic tissue 
property.B: The dimensional of the spring. 
 
To simulate mechanical property change in the liver tissue during the progression of liver 
fibrosis, we build a bead-and-spring model.  Each spring has a Young’s modulus E, area of cross-
section of spring A and length L between two nodes (l, j). θ is the intersection angle between the 
vector 𝑖𝑗⃗⃗ , and vector 𝑋𝑖⃗⃗  ⃗. (Figure 3-11) Assuming 𝐶 = 𝑐𝑜𝑠𝜃 and 𝑆 = 𝑠𝑖𝑛𝜃, so the element stiffness 
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Since each element has 4 degrees of freedoms (each node has two degrees freedoms: x and 
y), the whole stiffness matrix K should be 2n×2n, following 
{𝐾}{𝑈} = {𝐹} 
U is the displacement vector of the node; F is the load vector of the node. 
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Through bead-spring model, the elastic stiffness of liver tissue was measured by calculating 
Young’s modulus in the model. An external force was applied to the top and bottom boundaries 
of a tissue (Figure 3-8). Based on our calculation algorithm, each node has a displacement at each 
time step. A higher Young’s modulus value would show a more flexible condition of the tissue. 
Since the deformation of tissue requires the external physical force that could affect the following 
structure of simulation, the force value as a parameter in the model was changed to measure the 
elasticity of tissue. 
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Figure 3-8 A. The fiber randomly growth in the tissue. Red line is tissue structure. Blue 
region is fiber. B. Applied forces stress the liver tissue. 
 
3.4 Results 
In pixel-diffusion model, we calculate the concentration of toxin at each point. The higher 
concentration of toxins has a higher potential of leading to a dead cell. Dead cells leads to fiber 




Figure 3-9 Dead cell mapping in the progress of toxin diffusion at one simulation step. 
The white points correspond to fiber pixels.  means dead cells. orange lines outline the lobule 
(Hexagon). A is early stage of liver fibrosis. B is heavy stage of liver fibrosis. 
 
In Figure 3-9, the concentration of dead cells around portal trails is higher than in other 
areas, and the concentration at the boundary of the lobule is also higher than the central vein. That 
means the fiber begins to be released around portal trails, and then collagen deposited to construct 
the fiber bundle to separate the single lobule. Based on the understanding of the process of fiber 
filed, the simulation shows the gradual development of the fiber patterns, which in time enclose 
the lobule. As hepatocytes died in response to high level toxin, persistent damage the fiber 
deposition in the dead cell region.  
 
 
Figure 3-10: Representative histology images from the liver biopsy with Masson stain, 
show each stage of hepatic fibrosis.  Collagen and elastin fibers were stained blue. The hepatic 
cell was stained red. Courtesy of Dr. Wang Zhengyan of Shijiazhuang 5Th Hospital, China. 
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In figure 3-10, the definition of grading for liver fibrosis in the simulated fiber images still 
follows the METRIA system. At the F1 stage, the fibers were deposited around the portal vein. 
Then, fiber bundles were found in stage 2. After fiber bundles bridging two portal veins, the 
simulation enters the 3rd stage of liver fibrosis. In stage 4, fiber bundles closed the whole lobule. 
After converting the fiber pixel map to the bead-spring model, the liver tissue was strained 
by force in different stages of hepatic fibrosis, the young’s modulus of liver tissue is shown in 
Figure 3-11. The stiffness of the liver enhances with the fiber increase in the tissue, and the results 
indicate that hepatic fibrosis progression increases liver stiffness. 
After converting the fiber pixel map to the bead-spring model, the liver tissue was strained 
by force in different stages of hepatic fibrosis. The young’s modulus was used to represents the 
elastic of liver tissue. In the model, we vary the concentration threshold to modify the width of 
fiber. The width of the fiber is proportional to the stiffness of fiber. Ten stiffness levels were set 
into the model, and each level has the same difference with the neighbor. The liver tissue was 
strained by extra force under the ten levels. Each line shows Young’s modulus changes with fiber 
growth. In figure 3-13, Young’s modulus increases with time as fibrosis progression in simulation. 




Figure 3-11 Young’s modulus is varying in the fiber growth process.  𝐾𝑓𝑖𝑏𝑒𝑟 is the elastic 
coefficient of unit fiber. 𝑘𝑡𝑖𝑠𝑠𝑢𝑒 = 3 
The model simulates the fiber growth in 30, 60, 300, and 1000 simulation time steps. We 
summarize the mean Young’s modulus in each stage of liver fibrosis at each time step and make 
an box plot (Figure 3-12). The definition of each stage of liver fibrosis in the model follow the 
description of the METAVIR system. In the first stage of liver fibrosis, the fiber appears at the 
portal area, and the length of each fiber is less than 15% of the length of the boundary of the lobule 
(LBL). If the length of fiber is between 15% and 99% LBL, the liver fibrosis is in the second stage. 
In the third stage, the fiber bridge is formed, and the number of fiber bridge is less than 6. After 






Figure 3-12 Young’s modulus vs. stage of liver fibrosis. The simulation runs fiber growth 
in 30 times and 1000 times. Upper is 30 times and lower is 1000 times. 
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The fibers grow in the liver tissue randomly in 30 to 1000 times. The range of Young’s 
modulus of liver tissue at each stage was stable after running 30 times. The stiffness of the liver 
enhances with the fiber increase in the tissue, and the results indicate that later stages of hepatic 
fibrosis correspond to increase liver stiffness. In the figure 3-15, there is not much difference 
between 30 times and 1000 times.  The Young’s modulus is stable at F4 stage, which means that 
the most stiffness of liver has less variability in cirrhosis and easily be measured. On the contrary, 
the box plots in early stage (F1 and F2) has variability and are presented with whiskers.  So, the 
accuracy of measurement of liver fibrosis has lower accuracy in early stage.   
3.5 Discussions 
To determine the mechanical property change during the progression of liver fibrosis, we 
start from the molecular and cellular mechanisms to model toxin induced liver fibrosis.  We first 
use a diffusion equation to describe the concentration of toxin at each point in the liver tissue. The 
toxin diffusion developed a model of fibrosis growth that can simulate the fibrosis progression 
fiber by fiber based on the underlying molecular and cellular mechanisms. The fibrosis growth 
model was verified through the real liver biopsy images, wherein emergent patterns are seen as 
defining the characteristics of liver fibrosis. The ability of a model can recreate these patterns to 
indicate the stage of liver fibrosis in generating. It explains the hepatic fibrosis progression and the 
pattern of the fiber bundle in a different stage of liver fibrosis. Then we developed a mechanical 
model (bead-spring model) of the liver tissue based on the fibrosis growth model that shows 
mechanical results consistent with our understanding of fibrotic liver. 
The goal of the mechanical model was to examine the stiffness of liver tissue in fibrosis. 
The results reveal that the effective Young’s modulus of the tissue increases as increasing amount 
of fiber deposited in the liver. Thus, the model was used to test hypotheses on fiber patterns and 
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the mechanical properties in the liver. The model described the qualitative feature of hepatic 
fibrosis through different fiber patterns in the biological liver tissue. Finally, from the past studies 
in liver tissue biomechanics, many living tissues are inhomogeneous and more complex 
structures{references}. Hence, our future work will focus on developing an inhomogeneous 
model, which can reproduce the process of liver fibrosis in three dimensional and observe the inner 
situation changed, such as blood flow. The work, in this chapter, represents the first step in series 
research to develop a toxin-based interaction for modeling the process of liver fibrosis and the 
mechanisms of tissue changing. 
Interestingly, the low variability the Young’s modulus at F4 suggests that it would be easy 
to detect F4 stage of liver fibrosis though the stiffness value. However, the larger variabilities in 
the Young’s moduli at early stages of liver fibrosis means the staging based on tissue stiffness, 











4 AUTO-GRADING OF LIVER FIBROSIS IN LIVER TISSUE SLIDES 
Liver biopsy has been the gold standard evaluation for liver disease diagnoses in terms of 
grading or stages. Assessment of histopathological features for disease staging uses semi-
qualitative scoring systems, including Metavir, Ishak, Ishak-modified system, and Histological 
activity index (HAI) [100],[101]. However, the scoring systems are description and subject to 
observing variability. [40] The accuracy of grading liver biopsy depends on the experience of the 
interpreter. [102] Because of these limitations, we aim to build machine learning-based algorithms 
for improved liver fibrosis quantification and grading using histological slides, in order to 
complement the pathologists.  
Feature representations play an essential role in analyzing medical imaging. Based on the 
previous understanding of the architectural and structural feature of liver tissue in liver 
inflammation, it was assumed that fibers are generated around the portal area, bridging each portal 
vein to neighbors. [103] In grading stages of liver fibrosis, Ishak and Metavir are the two most 
popular grading systems and provide the estimation of liver fibrosis in liver biopsy. According to 
the description of the grading systems, several types of regions are observed from liver tissue, 
including blood vessels, capsule, structural collagen and hepatic cells. The study of all the 
mentioned components in an image builds the foundation of liver fibrosis analysis techniques. 
Although the some papers for auto-grading liver tissue slides have been published, they 
mainly use observed features from images as training data in deep learning directly. [104] The 
observed features include fiber morphology and gray-level matrix for each pixel. These methods 
in deep learning demand considerable computational power and a large number of data samples.  
To improve the analysis efficiency of imaging and reduce the number of needed training samples, 
we build a new logical rule-based algorithm to provide a robust framework for liver slides 
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classification via machine learning. The traditional algorithms estimate grading using the manual 
segmentation and feature extraction from the images. Since the lack of a standardized and robust 
method for making slides, the small sizes of stained area, including dopant and original fiber, 
inferior the assessment of liver fibrosis. The new algorithm converts slide images to the array of 
objects. The limitations of traditional algorithms are responded by the last numbers in the range of 
objects, which will be reduced influence for training. Here, we evaluate our new algorithm of auto-
grading liver biopsy with machine learning techniques including random forest, support vector 
machine, and artificial neural networks. At last, we summarize the algorithm into a web platform 
to support auto-grading liver tissue slide service. 
4.1 Materials and Methods 
Human liver tissues were scanned in Wuhan Tongji Hospital through our collaboration 
with Dr. Chen Yaobing A total of 492 human liver tissue slides were randomly separated into the 
training group and the validation group. The 393 tissue slides in the treatment group were assigned 
at the corresponding grading levels of F0, F1, F2, F3, and F4. The other 101 tissue slides in the 
control group were predicted after completing the training process.  
All the liver tissues were cut into 0.5 cm sections, embedded into paraffin blocks, and made 
Masson trichrome staining, which is used in the histological assessment. The blocks were 
sectioned into slides at 4µm thickness. The tissue was mordanted in Bouin’s solution for 15 
minutes, and then slides were washed in running tap water to remove all the picric acid (yellow 
color) from sections. The sections were stained in Weigert’s working hematoxylin for 10 minutes. 
This working solution is suitable for approximately 10 days. After rewashing the sections, the 
tissue was stained in Bievrich scarlet acid fuchsin. The Bievrich scarlet acid fuchsin can stain 
cytoplasm and muscle red. The slides were stained in Phosphotungstic/Phosphotungstic acid 
37 
solution, then  rinsed in distilled water three times before placed in 1% acetic acid solution for 1 
minute.  
The slides images were taken with a scanner (NanoZoomer S360) using a 40X objective 
lens. Each image was acquired from full-size liver tissue in the slide (Figure 4-1), where pink color 
stains normal hepatic cell, blue color stains collagen fiber, and the white space in tissue is blood 
vessel. 
 
Figure 4-1 The liver tissue in slide with Masson stain. Red corresponds to the liver cell. 
Blue corresponds to fiber. White corresponds to the vessel. Size: 16.2mm × 12mm, 36480 pixels 




To reduce potential bias, only one pathologist graded all slides, using the Metavir scoring 
system. After training the samples, the accuracy is not high enough. The ineffective solution maybe 
caused by the less data for machine learning. Because the size of images is large, we can cut images 
to increase the number of training data. In order to keep accurate staging for fibrosis in each image, 
we only split each of the 123 liver slides equally into 4, resulting in 492 images as training samples. 
4 should be the optimal number of cuts that maximize the number without sacrificing staging need. 
Fewer cuts could not match the model requirement. Each image was cut vertically and horizontally 
(figure 4-2). The samples staging distribute from F0 to F4 (Table 4.1-2). Within these samples, 
9.7% of all images are F0-1. Most of patients with early stage of liver fibrosis did not have any 
symptoms. 47% of all images are F2, because the diagnostic for F2 stage patients mainly depends 
on observing their liver tissue, other non-invasive methods could not give high accuracy detection. 
So patients with F2 have to be sliced liver tissue for pathology. For the cirrhosis patients, the doctor 
can diagnose pathology through touching the liver area on the body. This is the reason why our 
cirrhosis images is only 17%. 
Table 4.1-1 Biopsy samples distribute across fibrosis stages. 
Liver Fibrosis Stage Count Prob 
0 28 0.05691 
1 20 0.04065 
2 232 0.47154 
3 128 0.26016 
4 84 0.17073 
Total 492 1.00000 
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Figure 4-2 The whole image was cut into four pieces; each piece has the same stage of 
liver fibrosis. Resolution: 444 nm/pixel. 
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4.2 Features extraction 
We first converted the images from NDPI to TIFF using Python, then analyzed them using 
MATLAB (version 2019a). We first adjusted the binary models to label the boundary of each 
section, and then used color deconvolution to transform color images into digital images 
representing the stain concentrations. The tissue/background separation is implemented using the 
boundary of each section. Three component types, including fiber, vessel, and fibrous, are 
extracted from tissue images, based on color scale grading (Figure 4-3). Due to the existence of 
tissue regions such as blood clots and muscle tissue, the segments of less than 220 pixels were 
removed to eliminate any background and steatorrhea in the cell. Also, only the largest liver tissue 
in the image was retained before analyzing, because the largest tissue usually have most complete 
information. Each tissue was classified by the boundary. The largest liver tissue has the highest 
number of pixels in the boundary. 
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Figure 4-3. Image preprocessing. Left: Representative liver slide image with Masson stain: 
pink corresponds to healthy hepatic cells; white corresponds to the veins, blue corresponds to 
collagen fibers.  Middle: background removal and noise extraction from the original liver slides. 
Right: (Top) Segmented image with only vessels (yellow) includes portal vein, central vein, and 
other small vessels, and (Bottom) Segmented collagen fiber (white).  
 
4.3 Machine learning-based algorithm for automated fibrosis staging 
The full model was derived in two steps. In the first step, the fibers and vessels were 
detected from each image, as input training data for machine learning algorithms. The logistical 
rule was summarized from the description of the Metavir scoring system. The explanation for each 
stage of liver fibrosis mainly discusses the spatial relationship between fiber and vessel, and the 
spatial distribution of the fibers. In the early stage, the fibers accumulate near the portal veins and 
the amount decreases with increasing distance to the portal vein. As liver fibrosis progresses, fibers 
form dense bundles bridging the adjacent portal veins. 
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Analysis treating the single vein is the original point of the new reference frame, where the 
fiber first appears nearest to the vein and then diffuse to occupy all around the vein. In other words, 
the fiber circle was built. The fiber bundles form a long rectangle, starting from the boundary of 
the fiber circle, centering around the vessel (Figure 4-4). So, we design a model to compare the 
position of fiber relative to the vein in the slides. For each slide, we calculate the distance from 
each fiber pixel to the center of its nearest vein and plot the distance to the vein vs. the number of 
fiber pixels (Figure 4-5). We assume that the stage features of liver fibrosis will manifest on the 
histogram of the distances. The histogram shows two steps (Figure 4-5). The first step represents 
the fibers near the vessel. The area under curve of the step corresponds to the number of fibers 
around the portal vein and thus reflects the liver fibrosis level at the early stage. The appearance 
of the second step is a sign that the liver begins to form fiber bundle and fibrosis develops to more 
severe stages. The width of the second step is the average length of fiber bundles. According to 
the Metavir scoring system, the conspicuous fiber bundles mean the stage enters the F2 or higher 
stage. We tested this algorithm using simulated image from our fibrosis model (chapter III) and 




Figure 4-4 The fiber bundle forming a long rectangle starts from the portal area. The liver 
tissue was colored with Masson stained. Red corresponds to the liver cell. Blue corresponds to 
fiber. White corresponds to the vessel. The two arrows point to the portal area and fiber bundle. 




Figure 4-5 The number of fiber pixels vs. distance. The distance is an amount of space 
between the fiber pixels and the vein in the slice image. Upper: The curve which has short 
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one step represents to F1 stage. Lower: The curve which has the first and second step 
represents to F3-4 stage. 
 
Figure 4-6 The simulation results. A and B are fiber growth in the single lobule. White is 
fiber. B and D is the number of fiber pixel vs. distance which are corresponding to A and B. A 
and C are F1 stage. B and D are the F2 stages. 
 
We set the number of fiber pixels arrays of each tissue slide as the input data for machine 
learning. Each image was divided into four pieces; each piece has the same pathology and was 
resized to a standard size of 15000×15000 pixels to allow for automated image conversion. Then 
the model calculates all the distance between the fiber pixel and its nearest vessel.  
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Because of the large number of calculations, we used KdTree to improve the ability to find 
the location of the most adjacent vein. For machine learning, several methods, including Random 
Forest, the Nearest Neighbors, One vs. The Rest, Naïve Bays, and Support Vector Machine were 
used for training and testing purposes. The Random Forest was made by 30 trees, and the Nearest 
Neighbors set 15 neighbors in the model. The input has the stage and the number of pixels arrays. 
The final output contains possibility and outcomes corresponding to the liver fibrosis stage from 
F1 to F4. To compare the Performance of the features, we test the five machine learning algorithms 
based on the same liver slide images extracted. In the Random Forest model, we set 30 trees. In 
the Nearest Neighbors model, the number of neighbors is 15. In the Naïve Bayes, the alpha is 1, 
and binarize is 0.  
We first evaluated the proposed methodology using the original 123 liver slides images 
obtained from different patients with liver fibrosis or cirrhosis. We set these slides into 3 groups, 
including F1 vs. F2-F4, F1-2 vs. F3-4 and F1-3 vs. F4. After training the features, the cross-
validated performances of each machine learning model are shown in table 4.4-1. 
Table 4.3-1 The cross-validation value for each stage with different machine learning 
models (n= 123). 
 ≥F2 ≥F3 F4 
Random Forest 
Classifier 
0.39 0.32 0.29 
Support Vector 
Machine 
0.45 0.45 0.45 
One-vs-The-Rest 0.39 0.32 0.32 
Nearest Neighbors 0.33 0.33 0.33 
Naïve Bayes 0.2 0.2 0.2 
 
The results show low significance for the methodology in all five machine learning 
algorithms since the number of training images is not large enough. For more training samples, we 
cut the images into 4 pieces (Figure 4.6), to increase the number of training data. These pieces 
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have the same pathology report. The same features are extracted from the 492 images using 
previous methods. The size of each number array of features is 700. The cross-validated 
performances for the cut images are shown in table 4.4-2, the area under the ROC curve (AUC) 
values are in table 4.4-3. 
Table 4.3-2 The cross-validation value for each stage with different machine learning models. 
The number of images is 492. 
 ≥F2 ≥F3 F4 
Random Forest Classifier 0.94 0.68 0.83 
Support Vector Machine 0.9 0.57 0.83 
One Vs The Rest 0.82 0.53 0.69 
Nearest Neighbors 0.9 0.68 0.82 
Naïve Bayes 0.71 0.57 0.67 
 
Table 4.3-3 The AUC for each stage with different machine learning models. 
 ≥F2 ≥F3 F4 
Random Forest Classifier 0.972 0.736 0.842 
Support Vector Machine 0.947 0.736 0.842 
One Vs The Rest 0.608 0.467 0.6 
Nearest Neighbors 0.972 0.625 0.842 
Naïve Bayes 0.694 0.313 0.583 
 
The new results have high cross-validation accuracies in each machine learning model, 
especially for the Random Forest model, Support Vector Machine, and Nearest Neighbors model. 
The AUC values show that the Random Forest model, support Vector, and Nearest Neighbors 
model all have good accuracy predicting stage. The Random Forest model has the highest value 
in each stage, so we select the Random Forest model to be the predicting model (figure 4-7). 
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Figure 4-7 Random Forest for stratifying fibrosis stage. The numerical features which were 
derived from slices images act training features for random forest algorithm. 
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We build a fully automated methodology for grading liver fibrosis from liver slides. The 
Random Forest model has high cross-validation values, and AUC value was used to grade liver 
fibrosis. The new samples were classified by three predicting models, which indicate ≥F2, ≥F3, 
and F4. The first model prediction agrees with two grading results, ranging in [1:2] with a value 
of 1 labeling the fibrosis stage < F2, and a value of 2 for stages at F2-4 (Table 4.4-4).  
Table 4.3-4 The predicting value for classification combinations. F1 is [1 1 1], F2 is [2 1 
1], F3 is [2 2 1] and F4 is [2 2 2]. 
 ≥F2 ≥F3 F4 
F1 1 1 1 
F2 2 1 1 
F3 2 2 1 




In this chapter, we report a new, fully automated algorithm for fibrosis staging using slides 
stained with H&E and Masson. The numerical parameters derived from tissue images represent 
key features from METAVIR systems, such as portal fibrosis and fiber bundles. Our results show 
that the method can clearly distinguish between F1 and F3. The auto-grading methodology can 
score different patterns of fibrosis. Comparing with the deep learning algorithm, this method using 
machine learning decrease the number of training images under the supervision. Since the input is 
numerical parameters, the calculation of power required was reduced. CPU is up to this job.  
Meanwhile, the calculating/training time per each image for the standard reference is less than 15 
mins. Analyzing each liver slides images uses only 15 seconds. These advantages can lay a 
foundation for application, which is auto-grading liver fibrosis. 
The methodology successfully grades the liver fibrosis with high accuracy.  The proposed 
method is designed to avoid the error from human interaction and manual work. Comparing with 
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different machine learning algorithms, we demonstrate that a machine learning-based algorithm 
using the numerical features-Random Forest model scores best. This machine-learning assisted, 
fully automated quantification of liver fibrosis grading, is a candidate for high-performance 








5 THE DYNAMICS OF BLOOD FLOW IN LIVER 
Liver fibrosis has a strong correlation with other diseases, such as diabetes and cancer 
[105]. Over the past two decades, the understanding of physiology and pathophysiology in liver 
fibrosis, especially early diagnosis of liver fibrosis has played a significant role in has improved 
the quality of life for cirrhotic patients [106]. Currently, techniques being explored for diagnose 
liver fibrosis are categorized as mainly the invasive and noninvasive measurements. 
5.1 Existing liver fibrosis measurements 
Liver biopsy, as an invasive method, is still treated as the gold standard for diagnosing 
hepatic fibrosis. However, it has a number of problems. The accuracy of liver biopsy is only 65% 
- 75% when biopsies are between 15mm and 25mm in length [1]. The invasive procedure is a high 
risk of operation in some pathophysiology, such as liver cancer, and required the patients to suffer 
the pain [2]. On the other hand, current noninvasive methods, such as transient elastography, are 
not very sensitive because of instrument accuracy and the subjectivity of operators. 
Transient elastography (TE), as a proven technology of noninvasive procedure, uses the 
ultrasound wave to test the stiffness of the liver [107]. However, it is still limited by sample errors, 
instrument accuracy, and the subjectivity of operators. Because the liver is a large organ and deep 
in the body,  other tissues and organs may affect the activity of ultrasound to render the 
profibrogenic grading [108]. The ultrasound wave of transient elastography only measures one 
point of the liver to measure the stiffness value. 
We developed a new two-dimensional (2D) blood wave ultra-graphy (BDW) as a non-
invasive technology to measure liver fibrosis. It constructs a new relationship between the 
dynamics of blood flow and the mechanical properties of the liver tissue, since the mechanical 
property of the liver is modified by the growing fiber network[108]. Compared with TE, it is not 
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limited by the size of the detection zone.  Blood flows through the whole liver and carries the 
overall information of liver fibrosis. There are a few studies that applied the dynamics of blood on 
ultrasound images for liver fibrosis diagnosis, all of these studies found that cirrhosis can affect 
the blood flow and the velocity decrease.[109-112].  
The stiffness of liver can be observed clearly sometimes, especially for late stage fibrosis, 
which is a valid bedside diagnosis for cirrhosis. Many studies have proven that the mechanical 
property of the liver is modified by the growth fiber network [113].  
In the past decades, the research found that liver disease could affect the hepatic blood flow 
[114, 115]. The velocity of blood generally decreases with liver fibrosis progression [116]. 
However, there is no model nor data to accurately describe the dynamics of hepatic blood flow 
relative to liver fibrosis progression.  In this chapter, we aim to develop a mathematical model that 
connects hepatic blood flow and liver fibrosis and use clinical data to support our model 
predictions.  
5.2 Design and Model 
The blood entre the liver mainly through portal veins, travels through the liver, and then 
exit the liver from the hepatic vein. As liver fibrosis progresses, the increased stiffness of the liver 
affects blood flow in the portal vein {references}. The effect in the vessel comes from the fiber 
structure and the mechanism of blood flow in the vein. The vascular wall was constructed by three 
parts, including intima, media, and adventitia (Figure 5-1). The intima of vein is endothelial cells 
tissue and elastic internal, responsible for building the smooth inter-surface and provide a 
protective screen between tissue and blood. The media are constructed by smooth muscle cells to 
maintain an elastic vascular wall. The adventitia consists of fibroblast, which when activated 
produce and deposit fibers. 
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Based on the property of the muscle pump, smooth muscle contraction provides the 
primary motive power of flood flow in the vein. This muscle involves standing swell and contract, 
help to bring venous blood. The structure of the cross-section of the vein has elastica interna, 
smooth muscle cells, and fibroblasts. 
 
Figure 5-1 The structure of Vein. The intima of the vein is endothelial cells tissue and 
elastica interna. The media is smooth muscle cells, which is homogeneous tissue. The fibroblast 
locates in the adventitia. 
 
We developed a physical model, which construct a novel relationship between the 
dynamics of blood flow and the mechanical properties of the liver tissue. The algorithms are 
designed to analyze the ultrasound Doppler images from hepatic patients. These results support 
the hypothesis of the model and suggest the possibility of using the dynamics of blood to identify 
a new noninvasive diagnostic tool for liver fibrosis. 
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In a chronically injured site in the liver, myofibroblasts generate and release the fibers at 
the adventitia. In other words, a skeletal fiber network encloses the vein and weaken the smooth 
muscle swelling when the blood presses the intima of the vein. The elasticity of the vein was 
damaged with the deposition of fiber.  
When we assume elasticity of smooth muscle cells, the expansion and contraction of the 
vessel to pump blood flow can be modeled as a harmonic oscillator.  We label the lowest velocity 
of blood at A point and the highest velocity of blood at B point (Figure 5-2). 
 
Figure 5-2 Illustration of blood flow in hepatic veins as driven by the elastic smooth muscle 
cells. The velocity of blood at A point is the lowest. The vessel is swelling. The velocity of blood at 
B point is the highest. The vessel is under contraction. 
 
Each point on the wall of the vein keeps oscillating under the periodic contraction of the 
smooth muscle cells. Ignoring the damping effect of reducing energy, the equation of motion for 
each point along the vessel wall is described as  
𝑚?̈? + 𝑘𝑥 = 0, 
where m is mass of each point, k is the elastic coefficient of the smooth muscle, and x is the 
displacement of each point. Solving the motion equation, we have 
𝑥(𝑡) = 𝐴𝑐𝑜𝑠(𝜔𝑡 + 𝜑) 






In a fibrotic liver, when the fiber network encapsulates the vein, the elastic coefficient of the 
vessel wall increasing. In Chapter 2 we have introduced the mechanism of fiber response with 
liver fibrosis. 𝑘𝑓𝑖𝑏𝑟𝑜𝑠𝑖𝑠 is the elastic coefficient of the vascular wall under the fiber encapsulation. 





  , 
the vessel oscillation frequency is higher in fibrotic liver than in healthy liver.  Also, in the veins 
the velocity of blood is driven by the oscillation of vessel walls, we predict that the oscillatory 
features in blood flow in the veins also correlates with the stiffness of the vascular wall. 
Furthermore, because the blood entering portal veins, exiting through the hepatic vein, we expect 
that the difference of the blood flow between the portal vein and hepatic vein may reflect the degree 
of liver fibrosis. 
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Figure 5-3 Vein structure in the liver. In the liver, the blood flow from the portal vein into 
the liver and flow out from hepatic vein. 
 
To prove this predicted correlation, we measured the blood flow through ultrasound 
Doppler from the portal vein and hepatic vein, respectively (Figure 5-4).  
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Figure 5-4 The ultrasound image with blood flow in middle hepatic vein. The image from 
Shijiazhuang fifth hospital. 
 
Ultrasound Doppler imaging uses the high-frequency sound wave to view the blood flow 
in the liver. Since ultrasound Doppler is captured in real-time, the imagery could show the 
transformation of the velocity of blood with time. The wave pattern of blood was detached from 




Figure 5-5 Upper: ultrasound image for blood flow. Lower: The boundary of the wave 
pattern. The ultrasound wave pattern was detected from human liver and describe the blood flow 
in the hepatic vein. 
 
We selected four locations in the veins in the liver to measure the ultrasound Doppler 
images, including the entrance of the portal vein (PV), and the exit of the left (LHV), middle 
(MHV), and right hepatic vein (RHV), respectively. Then the Doppler signals, which measure the 
velocity of blood flow, were segmented from the ultrasound image. Since our model predicts that 
frequency is the signature parameter, we Fourier transform the time signals to the frequency 
domain, 𝑓(𝜉) = ∫ 𝑓(𝑡)
∞
−∞
𝑒−2𝜋𝑖𝑡𝜉𝑑𝑡, where  is frequency and t is time (Figure 5-6) 
 
 




The wave pattern actually includes most of the effects we are looking at in blood flow 
dynamics, so the peak values in a frequency domain plot, though similar to the frequencies of heart 
beating, vary and carry information of fiber modification to blood flow. Comparing the selected 
peak value from the entrance and exit ultrasound images, the difference of each value will yield 





Figure 5-7 Comparing each frequency pattern from a different vein in the liver. Upper: No 
frequency shift at F0 between portal vein and hepatic veins. Lower: Frequency shift between portal 




5.3.1 Clinical data 
Between Jun 2016 and October 2018, we performed ultrasound Doppler tests on 160 
patients in two hospitals. The age and gender information of 160 patients was summarized in table 
5.3-1. All test protocols followed the ethics guidelines and was approved by the ethics committee 
at the Zhongshan Hospital in Shanghai, and the Shijiazhuang Fifth Hospital in Shijiazhuang, 
China. 




Mean 43.377 Total 160 
0-30 23.75%(38) Male 65.63%(105) 








5.3.2 Blood wave ultra-graphy 
Ultrasound doppler signals were obtained by the Doppler US imaging machine (Philips, 
GE). For independent ultrasound, images were detected at the portal vein, left hepatic vein, middle 
hepatic vein, and right hepatic vein from each patient (Figure 5-3). The time of detecting blood 
flow for each image is 6.6 seconds, during which patients need to hold breath. 
 Four independent ultrasound images and the heartbeat were obtained from each patient. 
To control quality through the entire procedure, operators who have more than ten years of 
ultrasound experience were enrolled in this study. Any ultrasound images were considered as 
unqualified when no signal or little valuable pattern was obtained in the ultrasound machine.  
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5.3.3 Liver biopsy 
Liver biopsies were also taken from the same patients within four days of the ultrasound 
measurement, providing the gold standard for grading of liver fibrosis. Each biopsy was stained 
with Masson’s trichrome. Grading of all the biopsy was based on the METAVIR scoring system. 
The biopsy samples with sizes smaller than 15mm or failed stain, were excluded. 
5.3.4 Serological examinations 
All serological examinations were measured within four days of ultrasound detection. The 
white blood cell, hemoglobin (HGB), platelet (PLT), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), albumin (ALB), globulin 
(GLB), bilirubin (DBIL), blood ureanitrogen (BUN), serum creatinine (sCr), prothrombin time 
(PT), international normalized ration (INR) were recorded. The FIB-4 as biomarker model was 
calculated as FIB-4 = [age (year)] × [AST (U/L)]/[platelet count (109/L) × ALT (U/L)1/2][11]. 
5.3.5 Blood flow model in ultrasound image 
Four ultrasound images were analyzed following three steps: feature detection, feature 
analysis, and computational prediction. 
Doppler signals were cropped from ultrasound images, with a standard size of 800*1600 
pixels. The envelop of the signals were extracted, and Fourier transformed. The frequency 
difference between the portal vein and the averaged frequency of the hepatic veins is the value 
that correlates to liver fibrosis score. 
5.3.6 Statistical analysis 
All the statistical data were summarized as mean±SD, median and interquartile range 
(IRQ). Student’s t-test were applied to compare groups. Sensitivity, specificity, positive, and 
negative predicate values were calculated. The area under the receiver operating characteristic 
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(ROC) curve (AUC) is the evaluation metrics for checking the correctness in estimation of liver 
fibrosis stages. All data were tested between two groups, and the p-value of less than 0.01 
indicated a significant correlation. The statistical analyses were conducted using R software. 
5.4 Results 
The serological examinations were summarized in Table 5.4-1. P-value was calculated 
between variables and the stage of liver biopsies. 
Table 5.4-1 Baseline characters of patients. 
Variables mean ± SD P-value 
WBC 5.69±3.52 0.0204 
PLT (109/L) 189.76±80.2 1.496e-11 
ALT (IU/L) 71.31±76.47 0.5903 
GGT (IU/L) 86.97±133.87 0.1636 
ALB (g/L) 43.39±5.91 0.0006464 
HGB (g/L) 137.78±23.57 0.06645 
AST (IU/L) 53.04±66.12 0.9342 
BUN 4.54±1.26 0.7284 
sCr 63.97±13.74 0.7373 
PT (%) 11.71±3.23 0.001399 









*Statistical quantifications were demonstrated with 95% CI, when applicable. 
*Sensitivity and Specificity include the lowest and highest value. 
*BDW, blood flow (PV versus LHV, MHV, and RHV); FIB-4, fibrosis index based on 
four factors; PL, PV versus LHV; PM, PV versus MHV; PR, PV versus RHV; PLM, PV versus 
LHV and MHV; PLR, PV versus LHV and RHV; PMR, PV versus MHV and RHV. 
 
In the results, BDW demonstrated the highest AUC, sensitivity, and specificity compared 
with all other methods for classifying cirrhosis, ≥F3, and F2 (Table 5.4-2 and Figure 5-8). All the 
AUCs were statistically significant (p-value <0.001). AUCs of BDW start from 0.9473, 0.9425, 
and 0.9438 for three stages, respectively, which were 0.1703, 0.1508, and 0.1578 higher than the 
AUCs of FIB-4. The sensitivity and specificity also have better Performance than FIB-4 and other 
analyses. PMR, which only analysis MHV and RHV, has the second-highest AUCs. In the three 
single hepatic veins, MHV and RHV were better than LHV. Since LHV is near the heart, the noise 









Figure 5-8 ROC curves with BDW, FIB-4, PL, PM, PR, PLM, PLR, and PMR for the 
assessment of liver fibrosis stages, respectively. A. The ROC of cirrhosis (F4). B. The ROC of 
advanced fibrosis (F0-F2 versus F3-4). C. The Roc of significant fibrosis (F0-F1 versus F2-F4). 
 
To investigate if other confounding factors, such as age, gender, weight, and inflammation 
state would impact these results, we randomly selected three cohorts (n=120) from all the patients 
(n=160) to test correlation. For each fibrosis classification, the ROC of three cohorts always 
overlapped each other (Figure 5-9). The AUCs are not much different (Table 5.4-3). These results 









Figure 5-9 ROC curves with cohort 1, cohort 2, and cohort 3 for the assessment of liver 
fibrosis stages, respectively. A. The ROC of cirrhosis (F4). B. The ROC of advanced fibrosis (F0-
F2 versus F3-4). C. The Roc of significant fibrosis (F0-F1 versus F2-F4). The number of patients 
are 120 in each cohort. 
 
Table 5.4-3 Performance of cohort 1, cohort 2, and cohort 3 (n=???) for the assessment 
of liver fibrosis stages.  
AUC Sensitivity  Specificity 
Cirrhosis 

















   













   













For the three-strategy comparison, BDW showed similar performance. AUCs of BDW was 
significantly better than FIB-4 in all fibrosis stages. We compare BDW values and transient 
elastography results (Figure 5-10), and show that BDW distinguishes between healthy people and 




Figure 5-10 The values in liver fibrosis stages. A. The error bar shows the BDW versus the 
stage of liver fibrosis. B. The error bar shows the value of transient elastography versus the stage 




In this study, we developed a physical model to describe the dynamic of blood flow in the 
liver. The model improved the understanding of how the blood flows in the hepatic vein and how 
fibrosis affects the dynamics of blood flow. Based on this model, we measured the ultrasound 
Doppler images of PV, LHV, MHV, and RHV and calculated the frequency differences between 
the PV and the HVs as a measurement for liver fibrosis. For these data, the diagnostic accuracy of 
BDW was compared with FIB-4 and biopsy readings. In cirrhosis (F4), advanced fibrosis (>F3), 
and significant fibrosis, (>F2). BDW performed significant superiority against FIB-4 and others. 
BDW, with AUCs reaching 0.945, shows similar diagnostic accuracy compared to the reference 
standard liver biopsy. For assessing advanced fibrosis and significant fibrosis, PMR had the 
second-highest diagnostic accuracy, with AUCs were 0.8815 and 0.9048. In the cirrhosis, PLR 
showed the second-highest diagnostic accuracy with AUC of 0.8967. Comparing with three signal 
hepatic veins, LM had the highest AUC of 0.8007, 0.7486, and 0.8076, which did not show a 
significant difference in FIB-4 tests. 
To investigate the influence of other factors, such as age, weight, and inflammation, we 
analyzed three cohorts in ROCs. These factors did not show a significant impact on the 
performance of BDW. 
These results indicate that BDW can be used for the assessment of liver fibrosis and 
provides a high diagnostic accuracy in classifying liver fibrosis stages. This study is the first time 
to build a quantitative relationship between the hepatic blood flow and liver fibrosis, and 
demonstrates a novel non-invasive liver fibrosis diagnosis with high accuracy. However, the 
limitation of this study was the limited population size and the unbalanced stage distribution of the 
population. In further research, we will recruit more patients with both ultrasound measurements 
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and liver biopsy. We will also enroll patients of different chronic liver conditions, including HBV-
infected and NASH Patients. In conclusion, BDW performed a high diagnostic accuracy and has 






















The liver fibrosis can develop in patients with any type of chronic liver disease, including 
alcoholic liver disease, hepatitis C, hepatitis B, nonalcoholic fatty liver disease (NAFLD), and 
autoimmune hepatitis. Alcoholic liver disease is a leading cause of liver disease and liver-related 
deaths globally, particularly in developed nations. The Centers for Disease Control (CDC) 
estimates that 19,388 people died in the US from alcohol-related liver disease in 2014. Results of 
the 2015 National Survey on Drug Use and Health indicate that 15.1 million adults aging 18 and 
older struggle with alcohol use disorder. The CDC further estimates that approximately 3.2 million 
Americans are chronically infected with the hepatitis C virus, with an estimated 8,000 to 10,000 
hepatitis C virus-related deaths annually. By far, the largest and fastest-growing population at risk 
for developing hepatic fibrosis are individuals with NAFLD, which is often associated with one or 
more aspects of metabolic syndrome.  A significant number of people with NAFLD also have liver 
inflammation and fibrosis. This constellation of liver pathology is termed nonalcoholic 
steatohepatitis or NASH. GlobalData epidemiologists forecast that the total prevalence of NASH 
in the United States, the United Kingdom, France, Germany, Italy, Spain, and Japan will grow by 
an annual growth rate (AGR) of 0.64% per year over the next ten years, from 61,295,898 cases in 
2016 to 65,201,742 cases in 2026. In the 7MM, the US will have the highest number of total 
prevalent cases throughout the forecast period, with 34,972,594 cases in 2016 and 38,256,918 
cases in 2026. 
The key to preventing liver fibrosis from advancing to more deadly diseases, including 
cirrhosis and liver cancer, is to diagnose and reverse fibrosis in its early stage. Early stages of 
fibrosis, however, are challenging to detect because they are asymptomatic. Too often, when liver 
disease is first diagnosed, it is too late to avoid potentially fatal outcomes. Furthermore, evaluation 
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of treatment-efficacy of interventions to halt or reverse liver disease relies on assessing the stage 
of fibrosis. 
Existing technologies for fibrosis detection are 1) invasive, inaccurate, and risky (biopsy); 
or 2) noninvasive, expensive with severe shortcomings in terms of both accuracy and accessibility.  
To overcome these limitations and offer a more accurate non-invasive method for fibrosis 
detection, we conducted the following studies.  
First, we developed a fiber-pixels model for liver fibrosis, describing the critical interaction 
between hepatocytes and the fiber. The fiber-pixels model also builds the 2D image to simulate 
the fiber patterns in various liver fibrosis stages. These images can be supplemental training 
samples in machine learning or deep learning models.  
Second, we developed a new machine learning method to auto-stage liver fibrosis based 
on histopathological slides. Compared with other machine learning models, our numerical 
features-random forest model uses less than 15 seconds to analyze one biopsy image with clinical 
accuracy. 
Third, we developed a physics-based model to connect blood flow dynamics and stages of 
liver fibrosis.  Analysis on clinical data using Ultrasound Doppler measurements showed 
improvements compared with elastography and serologic measurements.  
Last, this new noninvasive fibrosis detection methods shows good translational potential, 
as it improves upon the state-of-the-art by offering a more accurate, safer, and more convenient 
noninvasive method of detection. The potential users are doctors and clinicians, hospitals, and 
other healthcare providers, ultrasound manufactures, as well as pharmaceutical companies for 
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